If you enjoy this content, please share it with a colleague
Volpara Solutions Limited
RELATED CONTENT
April 7 2020 — Volpara Solutions announced it is collaborating with DetectED-X, an online radiology training and ...
Celebrating its 10th Anniversary in 2019, Volpara Solutions remains committed to helping breast imaging centers achieve ...
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara products to breast imaging clinics in the United States, Australia, New Zealand and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the U.S. Food & Drug Administration (FDA).
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based MRS Systems Inc. (MRS).
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.
Volpara Solutions announced the launch of an expanded agreement enabling the worldwide distribution of its VolparaDensity software by GE Healthcare.
Volpara Solutions Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for new technologies used in the Volpara Density clinical application for breast density assessment. The updated version of VolparaDensity more accurately reflects breast density from images captured using the Hologic SmartCurve system.
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s artificial intelligence (AI)-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide an opportunity for ScreenPoint to enter the U.S. market.
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. 25–30 in Chicago. Its suite of cloud-based quantitative breast imaging analysis tools is designed to help maintain consistent quality in breast screening.
Volpara Solutions announced that the data stored in the Volpara Enterprise cloud now exceeds 1 million mammographic studies. Analysis of this anonymized big data, reflecting the state of mammography in 2018, helps mammography providers achieve improved mammographic sensitivity and detect breast cancers at an earlier stage. It also helps breast imaging centers better understand how their image quality compares to that of other facilities and how to improve their mammograms going forward.